Invivyd, Inc. (NASDAQ:IVVD) Director Sells $50,318.10 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 119,805 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10. Following the transaction, the director now owns 3,568,274 shares of the company’s stock, valued at approximately $1,498,675.08. This trade represents a 3.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The stock was sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total value of $34,099.20.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Price Performance

IVVD traded up $0.02 during trading on Thursday, reaching $0.53. 870,708 shares of the stock traded hands, compared to its average volume of 667,876. The stock’s 50-day simple moving average is $0.74 and its two-hundred day simple moving average is $0.99. Invivyd, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $5.20. The stock has a market cap of $63.44 million, a price-to-earnings ratio of -0.27 and a beta of 0.53.

Institutional Investors Weigh In On Invivyd

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC increased its holdings in Invivyd by 198.6% in the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after buying an additional 25,201 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Invivyd in the second quarter valued at approximately $263,000. Rhumbline Advisers grew its position in Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after acquiring an additional 82,164 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new position in shares of Invivyd during the 2nd quarter valued at $86,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on IVVD shares. Morgan Stanley decreased their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Invivyd in a research report on Thursday, November 21st. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, HC Wainwright lowered their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.